<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03223974</url>
  </required_header>
  <id_info>
    <org_study_id>2016BJYYEC-067-01</org_study_id>
    <nct_id>NCT03223974</nct_id>
  </id_info>
  <brief_title>Clinical Trial on Safety and Efficacy of Drug-coated Balloon in Treatment of Coronary Bifurcation Lesions</brief_title>
  <acronym>BJDCB-BIF</acronym>
  <official_title>Clinical Trial on Safety and Efficacy of Drug-coated Balloon in Treatment of Coronary Bifurcation Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of paclitaxel-coated&#xD;
      balloon in treatment of coronary bifurcation lesions. This is a feasible study to demonstrate&#xD;
      the noninferiority of paclitaxel Drug-coated balloon(DCB) only strategy for bifurcation&#xD;
      lesions when compared with traditional single drug eluting stent(DES) strategy, so as to&#xD;
      simplify the procedure for treatment of coronary bifurcation lesions and extending the&#xD;
      clinical indications of paclitaxel DCB in China.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Paclitaxel DCB is designed to release anti-proliferative agents to the whole lesion rapidly&#xD;
      and homogenously to inhibit excessive neointima proliferation and is associated with rapid&#xD;
      healing of endothelium. As a result, DCB therapy reduces the risk of coronary thrombosis.&#xD;
      Since only 1 to 3 months duration of dual anti-platelet therapy is required, the bleeding&#xD;
      risk associated with prolonged dual anti-platelet therapy (DAPT) is reduced by DCB.&#xD;
      Furthermore, there is no permanent residue of foreign bodies in the blood vessels after DCB&#xD;
      procedure and this advantage completely eliminates adverse events associated with allergic&#xD;
      reactions to metal, polymer and stent fracture. For side branch(SB) with a relatively small&#xD;
      lumen in bifurcation lesions, DCB may neglect the lumen loss due to stent scaffolds and cause&#xD;
      much less late lumen loss (LLL) than stent therapy does. For main branch(MB), no jailed SBs&#xD;
      by the stent and the rate of SB stenosis or even occlusion will be greatly reduced.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 16, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Actual">November 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>QCA(quantitative coronary analysis) of efficacy of DCB</measure>
    <time_frame>Follow-up coronary angiography at 9 months after the procedure</time_frame>
    <description>late lumen loss, minimal lumen diameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>device-related ischemic events</measure>
    <time_frame>Clinical follow up at 30 days, 6, 9, 12 and 24 months after the procedure</time_frame>
    <description>including cardiovascular death, target vessel related myocardial infarction and ischemia-driven revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient-related ischemic events</measure>
    <time_frame>Clinical follow up at 30 days, 6, 9, 12 and 24 months after the operation</time_frame>
    <description>all myocardial infarction , any revascularization and all-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARC（Academic Research Consortium） defined target vessel thrombus events</measure>
    <time_frame>Clinical follow up at 30 days, 6, 9, 12 and 24 months after the operation</time_frame>
    <description>definite, probable and possible target vessel thrombus</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Paclitaxel DCB for MB and/or SB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM(atmosphere), lasting for &gt;30 seconds</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DES in MB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>with regular techniques</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel DCB</intervention_name>
    <description>Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM, lasting for &gt;30 seconds. If quantitative coronary angiography determines residual stenosis ≤ 30% , it is considered to be a successful operation.</description>
    <arm_group_label>Paclitaxel DCB for MB and/or SB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DES</intervention_name>
    <description>MB should be sufficiently predilated to facilitate the positioning of the stent and the stent residual stenosis should be ≤10% to be a successful operation.</description>
    <arm_group_label>DES in MB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient-related criteria：&#xD;
&#xD;
               -  Patients with stable angina, unstable angina, old myocardial infarction or&#xD;
                  evidence of asymptomatic myocardial ischemia and consent to receive coronary&#xD;
                  intervention therapy;&#xD;
&#xD;
               -  Aged between 18 and 80 years;&#xD;
&#xD;
               -  Consent to receive angiographic follow up at 9 months and clinical follow up at&#xD;
                  30 days, 6, 9, 12 and 24 months.&#xD;
&#xD;
          -  Lesion-related criteria：&#xD;
&#xD;
               -  Target lesions of Medina (0,1,1), (1,0,1) or (1,1,1) primary coronary bifurcation&#xD;
                  lesions without previous intervention therapy;&#xD;
&#xD;
               -  MB reference vessel diameter between 2.5 mm and 3.5 mm and length ≤30mm; SB&#xD;
                  reference vessel diameter between 2.0 mm and 3.0 mm and length ≤22 mm;&#xD;
&#xD;
               -  Pre-operative vessel diameter stenosis must ≥70% or ≥50% associated with local&#xD;
                  ischemia;&#xD;
&#xD;
               -  After lesion predilation, no dissection is seen, or type A/B dissection can be&#xD;
                  seen, residual stenosis ≤30% and TIMI(thrombolysis in myocardial infarction)&#xD;
                  grade 3 flow;&#xD;
&#xD;
               -  The distance between other lesions requiring intervention therapy and the target&#xD;
                  lesion must &gt;10mm ;&#xD;
&#xD;
               -  Only one drug-eluting balloon or drug-eluting stent is used in treatment of MB&#xD;
                  and SB lesions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient-related criteria：&#xD;
&#xD;
               -  Myocardial infarction in the previous week;&#xD;
&#xD;
               -  Severe congestive heart failure[LVEF &lt;30% or NYHA( New York Heart Association)&#xD;
                  III/IV)]&#xD;
&#xD;
               -  Severe valvular heart disease;&#xD;
&#xD;
               -  Pregnant or breastfeeding women;&#xD;
&#xD;
               -  Life expectancy no more than 1 year or factors causing difficulties in clinical&#xD;
                  follow up;&#xD;
&#xD;
               -  Bleeding predisposition, contraindications of anticoagulants or antiplatelet&#xD;
                  agents;&#xD;
&#xD;
               -  Intolerance to aspirin and/or clopidogrel;&#xD;
&#xD;
               -  Known intolerance or allergy to heparin, contrast agents, paclitaxel, iopromide,&#xD;
                  rapamycin, polylactic acid-glycolic acid copolymer, Co-Cr alloy or&#xD;
                  platinum-chromium alloy;&#xD;
&#xD;
               -  Leukopenia or thrombopenia;&#xD;
&#xD;
               -  A history of peptic ulcer or GI bleeding in the previously;&#xD;
&#xD;
               -  Stroke within 6 months prior to the operation;&#xD;
&#xD;
               -  A history of severe hepatic or renal failure.&#xD;
&#xD;
          -  Lesion-related criteria ：&#xD;
&#xD;
               -  Extensive thrombosis in the target vessel;&#xD;
&#xD;
               -  Percutaneous coronary intervention of the graft vessel;&#xD;
&#xD;
               -  Chronic total occlusions (pre-operative TIMI grade 0 flow);&#xD;
&#xD;
               -  Left main branch lesions and /or three-vessel lesions requiring treatment;&#xD;
&#xD;
               -  Lesions that are not indications of PTCA(percutaneous transluminal coronary&#xD;
                  angiography) or other intervention therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xue Yu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 15, 2017</study_first_submitted>
  <study_first_submitted_qc>July 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Hospital</investigator_affiliation>
    <investigator_full_name>Xue Yu</investigator_full_name>
    <investigator_title>Project manager</investigator_title>
  </responsible_party>
  <keyword>Angioplasty</keyword>
  <keyword>drug-coated balloon</keyword>
  <keyword>bifurcation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

